anti-GPRC5D/anti-CD3/anti-BCMA trispecific T-cell engager (Integral Molecular)

N/A

Report date: 2026/03/19 16:52:55

Base Information

Drug Nameanti-GPRC5D/anti-CD3/anti-BCMA trispecific T-cell engager (Integral Molecular)
Drug Alias Nameanti-GPRC5D/anti-CD3/anti-BCMA trispecific antibody (Integral Molecular)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionTumor necrosis factor ligand superfamily member 13 modulatorsImmunostimulantsT lymphocytes stimulants +[5] 
TargetsG-protein coupled receptor family C group 5member DTumor necrosis factor ligand superfamily member 13T cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesIntegral Molecular Inc
China Registration ClassN/A

Develop Information

Active CompaniesIntegral Molecular Inc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A